ClinicalTrialsFinder

BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) Clinical Trials in Wuhan, Hubei

1 recruitingWuhan, Hubei, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd30 enrolled1 locationNCT06690827